One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Carbamylated NETs promote bone erosion in RA
Jessica McHughÂÂ
doi : 10.1038/s41584-023-00938-0
Volume 19 Issue 4, April 2023
VEXAS syndrome more common than originally thought?
Sarah OnuoraÂÂ
Diabetes increases risk of end-stage renal disease in SLE
Jessica McHughÂÂ
Nanobody targets TNF and IL-6 for additive efficacy
Robert PhillipsÂÂ
New biomarker panel best yet for prediction of OA progression
Robert PhillipsÂÂ
Co-trimoxazole reduces mortality in anti-MDA5-DM
Robert PhillipsÂÂ
PPM1A: TGFβ regulator and therapeutic target in OA
Jessica McHughÂÂ
Allogeneic iPSC-derived organoids repair articular cartilage
Robert PhillipsÂÂ
The new look of classification criteria for systemic vasculitis
Giacomo Emmi & Augusto VaglioÂ
Inflammation and DNA damage: cause, effect or both
Antonio Pezone, Fabiola Olivieri, Maria Vittoria Napoli, Antonio Procopio, Enrico Vittorio Avvedimento & Armando GabrielliÂ
doi : 10.1038/s41584-022-00905-1
Inflammation is a biological response involving immune cells, blood vessels and mediators induced by endogenous and exogenous stimuli, such as pathogens, damaged cells or chemicals. Unresolved (chronic) inflammation is characterized by the secretion of cytokines that maintain inflammation and redox stress.
State-of-the-art evidence in the treatment of systemic sclerosis
Janet E. Pope, Christopher P. Denton, Sindhu R. Johnson, Andreu Fernandez-Codina, Marie Hudson & Tatiana NevskayaÂ
doi : 10.1038/s41584-023-00909-5
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ involvement, fibrosis and vasculopathy.
Treatment of lupus nephritis: consensus, evidence and perspectives
Chi Chiu Mok, Y. K. Onno Teng, Ramesh Saxena & Yoshiya TanakaÂ
doi : 10.1038/s41584-023-00925-5
Despite the continuing development of immunomodulatory agents and supportive care, the prognosis associated with lupus nephritis (LN) has not improved substantially in the past decade, with end-stage kidney disease still developing in 5–30% of patients within 10 years of LN diagnosis.
Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis
Joshua L. Bennett, Arthur G. Pratt, Richard Dodds, Avan A. Sayer & John D. IsaacsÂ
doi : 10.1038/s41584-023-00921-9
Sarcopenia, a disorder that involves the generalized loss of skeletal muscle strength and mass, was formally recognized as a disease by its inclusion in the International Classification of Diseases in 2016. Sarcopenia typically affects older people, but younger individuals with chronic disease are also at risk.
Author Correction: Glycobiology of rheumatic diseases
Theresa Kissel, René E. M. Toes, Thomas W. J. Huizinga & Manfred WuhrerÂ
